Cipla Stock

Cipla ROA

The Return on Assets (ROA) of Cipla (CIPLA.NS) as of Aug 24, 2026 is 14.10 %. In the previous year, Return on Assets (ROA) was 12.60 % — a change of 11.95% (higher).

ROA

14.10 %

YoY

11.95%

Last updated:

In 2026, Cipla's return on assets (ROA) was 14.10 %, a 11.95% increase from the 12.60 % ROA in the previous year.

The Cipla ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
6.17 INR
Jan 1, 2019
6.38 INR
Jan 1, 2020
6.54 INR
Jan 1, 2021
9.56 INR
Jan 1, 2022
9.29 INR
Jan 1, 2023
9.51 INR
Jan 1, 2024
12.60 INR
Jan 1, 2025
14.10 INR
The Cipla ROA history
YEARROAYoY
14.10 %+11.95%
12.60 %+32.47%
9.51 %+2.40%
9.29 %-2.87%
9.56 %+46.30%
6.54 %+2.52%
6.38 %+3.33%
6.17 %+28.97%
4.78 %-25.68%
6.44 %-14.70%
7.55 %-27.15%
10.36 %—
Access this data via the Eulerpool API
Get Free API Key

Cipla Stock analysis

What does Cipla do? Cipla Ltd is an Indian pharmaceutical company based in Mumbai. The company was founded in 1935 and is now one of the largest producers of generics worldwide. The name "Cipla" is an abbreviation for "Chemical, Industrial & Pharmaceutical Laboratories". Business Model: Cipla specializes in the production of high-quality generics. This means that they manufacture medication that has the same active ingredients as the original drugs. This allows them to offer medication at a significantly lower price. However, Cipla not only offers generics but also develops its own innovative medication. The focus is on therapy areas such as oncology, respiratory diseases, HIV/AIDS, diabetes, and cardiovascular diseases. Divisions: Cipla is divided into several divisions, including generics, specialty drugs, and biologics. The generics division is the company's core competence. Here, Cipla produces a variety of medications in different forms, such as tablets, capsules, suspensions, etc. The specialty drugs division focuses on innovative medications that are usually more expensive than generics. This includes medications for the treatment of cancer or autoimmune diseases. In the biologics division, Cipla produces biotechnology products based on the use of living cells. Products: Cipla offers a wide range of products, including medications for asthma, diabetes, hypertension, and infectious diseases. Some of the most well-known medications are Escitalopram (an antidepressant), Seroflo (an asthma medication), Tenofovir (an HIV medication), and Sorafenib (a cancer medication). The company continuously works on new products and invests heavily in research and development. Cipla also has a social responsibility. The company is involved in the fight against HIV/AIDS and produces life-saving medication for this disease at an affordable price. Furthermore, Cipla has launched a program called "Cipla Foundation" which works towards improving healthcare in developing countries. Overall, Cipla has achieved impressive growth and is now one of the most significant pharmaceutical companies worldwide. The company has proven that it is possible to offer high-quality medication at an affordable price and still be successful. Cipla is one of the most popular companies on Eulerpool.

ROA Details

Understanding Cipla's Return on Assets (ROA)

Cipla's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Cipla's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Cipla's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Cipla’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Cipla stock

Return on Assets (ROA) of Cipla is 14.10 % in 2026.

Return on Assets (ROA) of Cipla changed from 12.60 % to 14.10 %, representing a 11.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Cipla since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Cipla with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API
Get Free API Key

Profitability — Cipla

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Cipla